I-Mab Stock Discussion

Gapping up
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US)$ +11.3%, $Cardiff Oncology(CRDF.US)$ +9%, $Immatics(IMTX.US)$ +8.3%, $IDEAYA Biosciences(IDYA.US)$ +8%, $Lyra Therapeutics(LYRA.US)$ +5.7%, $POINT Biopharma(PNT.US)$ +5.7%, $Edgewise Therapeutics(EWTX.US)$ +4.7%, $Concert Pharmaceuticals(CNCE.US)$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US)$ +3.2%, $Veracyte(VCYT.US)$ +2.6%, $SpringWorks Therapeutics(SWTX.US)$ +2.3%,...

this one is going on the watch list
$I-Mab(IMAB.US)$
this pharmaceutical company has tons of potential big money makers in the pipeline. if just one of these Cancer drugs gets approved then it will be a lot of money to be made for this very cheap ticker. they're also anticipating being listed in mainland China and in Hong Kong. this could be a bullish catalyst in the future even without any of the drugs being approv...

Gainers:
• $GTY Technology(GTYH.US)$ +118.1% (entered into a definitive agreement to be acquired by GI Partners )
• $Finch Therapeutics(FNCH.US)$ +68.33% (announces removal of FDA clinical hold on CP101 IND)
• $Zymeworks(ZYME.US)$ +42.34% (confirms receipt of non-binding proposal from All Blue Falcons for $10.50 per share in cash)
• $Hub Group(HUBG.US)$ +16.3% (earnings reports)
• $Lantheus(LNTH.US)$ +14.2% (earnings reports)
• $Mohawk Industries(MHK.US)$ +13.7% (e...

Gainers:
• $AlloVir(ALVR.US)$ +23.11% (announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to its lead investigational multi-virus-specific T cell therapy posoleucel)
• $I-Mab(IMAB.US)$ +13% (report that the company is considering sale)
• $ASML Holding(ASML.US)$ +5.2% (earnings report)
• $Humanigen(HGEN.US)$ +4.4% (Announces Peer-Reviewed Publication Demonstrating the P...

$I-Mab(IMAB.US)$ why dropped so much this week? any triggers?

$Shineco(TYHT.US)$ I heard that Shanggao is talking with the Stem cell Research Center of Harvard Medical School about the acquisition. Once the negotiation is successful, the price may soar to 500 DOLLARS, because the market value of similar companies is over 10 billion dollars, while the current market value of TYHT is only close to 100 million dollars, so the potential is infinite... $Genetron(GTH.US)$ $I-Mab(IMAB.US)$

$I-Mab(IMAB.US)$ Earnings per share is 2.28, which is very good. Let's get $85 first.